...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the Society for Gynecologic Investigation >Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
【24h】

Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.

机译：Bcl-2受体在子宫平滑肌肿瘤患者中的表达：免疫组织化学分析，比较平滑肌瘤，恶性潜能不确定的子宫平滑肌瘤和平滑肌肉瘤。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Bcl-2 protein is an apoptosis-inhibiting gene product that prevents the normal course of apoptotic cell death in a variety of cells. Additionally, bcl-2 can promote cell replication by reducing the requirement for growth factors. This protein seems, therefore, to play an important role in the growth of tumors. Our aim was to investigate the different expression of bcl-2 in uterine leiomyomas, smooth muscle tumors of uncertain malignant potential (STUMP), and leiomyosarcomas (LMS). Furthermore, the correlation between bcl-2 expression and various clinicopathologic parameters in leiomyosarcomas was assessed to evaluate its prognostic value. METHODS: This study included 26 cases of leiomyoma, 22 cases of STUMP, and 21 cases of LMS of the uterus. Bcl-2 expression was investigated by immunohistochemistry from paraffin-embedded tissue. The immunohistochemical findings were compared and correlated with different clinicopathologic parameters. Clinical information, including follow-up data, was obtained from the database of the Department of Gynecology and Obstetrics. RESULTS: Bcl-2 was present in 12 of 21 LMS, eight of 22 STUMP, and 20 of 25 leiomyomas. Significant differences regarding the frequency of bcl-2 expression and the staining intensity were observed between LMS and leiomyoma as well as between STUMP and leiomyoma (P <.05) but not between LMS and STUMP (P >.05). Regarding the outcome of uterine LMS, patients with bcl-2 positive tumors showed less vascular space involvement and longer overall survival (P <.05). CONCLUSION: Bcl-2 was expressed more frequently and more strongly in leiomyomas compared with LMS and STUMP. Regarding the outcome of uterine LMS, patients with bcl-2-positive tumors showed less vascular space involvement and longer overall survival. The stronger bcl-2 expression in benign leiomyomas and the better clinical outcome of bcl-2-positive LMS indicate that this protein seems to act as a good prognostic factor. Further studies including larger numbers of patients are necessary to establish bcl-2 as a routine marker for improved prognosis in malignant uterine smooth muscle tumors.
机译：目的：Bcl-2蛋白是一种凋亡抑制基因产物，可防止多种细胞凋亡的正常过程。另外，bcl-2可以通过减少对生长因子的需求来促进细胞复制。因此，这种蛋白质似乎在肿瘤的生长中起重要作用。我们的目的是研究子宫平滑肌瘤，恶性潜能不确定的平滑肌肿瘤（STUMP）和平滑肌肉瘤（LMS）中bcl-2的不同表达。此外，评估了平滑肌肉瘤中bcl-2表达与各种临床病理参数之间的相关性，以评估其预后价值。方法：本研究包括26例平滑肌瘤，22例STUMP和21例子宫LMS。通过免疫组织化学从石蜡包埋的组织中研究Bcl-2表达。比较了免疫组织化学结果，并将其与不同的临床病理参数相关联。临床信息，包括随访数据，从妇产科数据库获得。结果：Bcl-2存在于21个LMS中的12个，22个STUMP中的8个和25个平滑肌瘤中的20个。在LMS和平滑肌瘤之间以及STUMP和平滑肌瘤之间观察到关于bcl-2表达频率和染色强度的显着差异（P <.05），但在LMS和STUMP之间未观察到（P> .05）。关于子宫LMS的结果，bcl-2阳性肿瘤患者的血管间隙受累少，总生存期更长（P <.05）。结论：与LMS和STUMP相比，Bcl-2在平滑肌瘤中表达更为频繁和强烈。关于子宫LMS的结局，bcl-2阳性肿瘤患者的血管空间受累少，总生存期更长。良性平滑肌瘤中bcl-2表达越强，bcl-2阳性LMS的临床效果越好，表明该蛋白似乎是良好的预后因素。建立bcl-2作为改善恶性子宫平滑肌肿瘤预后的常规标志物，有必要进行包括大量患者在内的进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号